Studies in the modulation of experimental autoimmune encephalomyelitis.
Experimental autoimmune encephalomyelitis (EAE), an experimental model for multiple sclerosis, can be induced through inoculation with several different central nervous system (CNS) proteins or peptides. Modulation of EAE, resulting in either protection from EAE or enhancement of EAE, can also be accomplished through either vaccination or DNA immunization with molecular mimics of self-CNS proteins. Previously published data on this method of EAE modulation will be reviewed. New data is presented, which demonstrates that EAE can also be modulated through the administration of the beta-(1,3)-D-glucan, curdlan. Dendritic cells stimulated by curdlan are involved in the differentiation of the interleukin-17 producing subset of CD4(+) T cells that are recognized effector cells in EAE. Using two different systems to study the effects of curdlan on EAE, it was found that curdlan increased the incidence of EAE and/or the severity of the disease course.
Libbey
Jane E
JE
Department of Pathology, University of Utah School of Medicine, 30 North 1900 East, 3R330 SOM, Salt Lake City, UT 84132, USA.
Tsunoda
Ikuo
I
Fujinami
Robert S
RS
D000818:Animals; D004681:Encephalomyelitis, Autoimmune, Experimental / Q000139:chemically induced / Q000188:drug therapy* / Q000276:immunology / Q000517:prevention & control; D006801:Humans; D009419:Nerve Tissue Proteins / Q000378:metabolism; D009479:Neuropeptides / Q000378:metabolism; D018696:Neuroprotective Agents / Q000627:therapeutic use; D047071:beta-Glucans / Q000494:pharmacology
D009419:Nerve Tissue Proteins; D009479:Neuropeptides; D018696:Neuroprotective Agents; D047071:beta-Glucans; C038459:curdlan
Int Rev Neurobiol. 2007;79:73-97
17531838
J Neuroimmunol. 2008 Nov 15;204(1-2):92-100
18706703
Curr Med Chem. 2008;15(19):1899-910
18691047
J Neuroimmunol. 1997 May;75(1-2):75-83
9143240
J Immunol. 2001 Jun 15;166(12):7579-87
11390514
Curr Opin Microbiol. 1999 Aug;2(4):392-7
10458987
Chem Immunol. 1989;46:101-25
2482036
Nihon Rinsho Meneki Gakkai Kaishi. 2009 Feb;32(1):20-8
19252374
J Neuropathol Exp Neurol. 1996 Jun;55(6):673-86
8642393
Immunity. 2001 Jul;15(1):15-22
11485734
J Immunol. 1999 Mar 15;162(6):3336-41
10092787
J Immunol. 1994 Nov 15;153(10):4349-56
7525700
J Neuroimmunol. 1993 Apr;44(1):15-25
7684398
Autoimmunity. 2006 Feb;39(1):9-19
16455578
J Neuroimmunol. 2007 Aug;188(1-2):22-33
17604850
J Exp Med. 2001 Sep 3;194(5):669-76
11535634
Ann N Y Acad Sci. 2007 Apr;1103:157-66
17376824
Brain Pathol. 2007 Apr;17(2):219-29
17388953
J Autoimmun. 2001 May;16(3):229-34
11334487
J Exp Med. 2005 Jan 17;201(2):233-40
15657292
Curr Top Microbiol Immunol. 2006;311:117-53
17048707
J Immunol. 2007 Feb 1;178(3):1372-8
17237384
Nat Immunol. 2009 Feb;10(2):203-13
19122653
J Neuropathol Exp Neurol. 1998 Aug;57(8):758-67
9720491
J Neuroimmunol. 1999 May 3;96(2):148-57
10337913
Ann N Y Acad Sci. 2008 Nov;1143:35-44
19076343
Curr Drug Targets Inflamm Allergy. 2005 Apr;4(2):239-45
15853746
Immunol Rev. 2006 Jun;211:164-81
16824126
J Neurovirol. 2001 Jun;7(3):220-7
11517396
Neurochem Res. 1994 Aug;19(8):915-21
7528354
Nat Immunol. 2007 Jun;8(6):630-8
17450144
Recent Pat Biotechnol. 2007;1(1):59-73
19075833
Nat Immunol. 2006 Nov;7(11):1151-6
16998492
Nature. 1986 Nov 20-26;324(6094):258-60
2431317
Int Immunopharmacol. 2009 May;9(5):575-81
19539560
Allergol Int. 2008 Jun;57(2):115-20
18427164
J Exp Med. 2005 Mar 21;201(6):949-60
15781585
Proc Natl Acad Sci U S A. 2009 Jan 20;106(3):876-81
19136631
Semin Immunol. 2004 Oct;16(5):335-47
15528078
Appl Microbiol Biotechnol. 2005 Aug;68(2):163-73
15818477
J Exp Med. 2005 Feb 21;201(4):523-33
15710651
J Neuroimmunol. 1996 Feb;64(2):163-73
8632058
Neurochem Res. 1994 Aug;19(8):935-44
7528355
Results Probl Cell Differ. 2010;51:21-42
19130026